AD-2071 + AD-2072

AD-2071 + AD-2072 is a fixed-dose combination or coadministration of two investigational small molecule drugs, currently under evaluation for their pharmacokinetic interaction, safety, and tolerability in healthy adult volunteers. The combination has been studied in phase 1 clinical trials primarily sponsored by Addpharma. The main therapeutic focus appears to be on cardiovascular and metabolic diseases such as hypertension and hyperlipidemia. While the precise molecular identities of AD-2071 and AD-2072 are not publicly disclosed, trial endpoints include pharmacokinetics of agents like ezetimibe, rosuvastatin, telmisartan, and amlodipine—suggesting that these or similar compounds may be involved in the formulation[3][6]. The mechanism(s) of action are not explicitly stated but likely relate to lipid-lowering or antihypertensive effects.